Department of Anesthesiology, University of Illinois at Chicago, Illinois, United States of America.
University of Arizona Health Sciences, Tucson, Arizona, United States of America.
PLoS One. 2018 Dec 27;13(12):e0209861. doi: 10.1371/journal.pone.0209861. eCollection 2018.
The pattern of binding of monoclonal antibodies (mAbs) to 18 epitopes on human angiotensin I-converting enzyme (ACE)-"conformational fingerprint of ACE"-is a sensitive marker of subtle conformational changes of ACE due to mutations, different glycosylation in various cells, the presence of ACE inhibitors and specific effectors, etc.
METHODOLOGY/PRINCIPAL FINDINGS: We described in detail the methodology of the conformational fingerprinting of human blood and tissue ACEs that allows detecting differences in surface topography of ACE from different tissues, as well detecting inter-individual differences. Besides, we compared the sensitivity of the detection of ACE inhibitors in the patient's plasma using conformational fingerprinting of ACE (with only 2 mAbs to ACE, 1G12 and 9B9) and already accepted kinetic assay and demonstrated that the mAbs-based assay is an order of magnitude more sensitive. This approach is also very effective in detection of known (like bilirubin and lysozyme) and still unknown ACE effectors/inhibitors which nature and set could vary in different tissues or different patients.
CONCLUSIONS/SIGNIFICANCE: Phenotyping of ACE (and conformational fingerprinting of ACE as a part of this novel approach for characterization of ACE) in individuals really became informative and clinically relevant. Appreciation (and counting on) of inter-individual differences in ACE conformation and accompanying effectors make the application of this approach for future personalized medicine with ACE inhibitors more accurate. This (or similar) methodology can be applied to any enzyme/protein for which there is a number of mAbs to its different epitopes.
单克隆抗体(mAbs)与人类血管紧张素转化酶(ACE)上的 18 个表位结合的模式——ACE 的“构象指纹”——是 ACE 由于突变、不同细胞中不同的糖基化、ACE 抑制剂和特定效应物的存在等导致的细微构象变化的敏感标志物。
方法/主要发现:我们详细描述了人类血液和组织 ACE 构象指纹的方法学,该方法允许检测来自不同组织的 ACE 表面拓扑结构的差异,以及检测个体间的差异。此外,我们比较了使用 ACE 构象指纹(仅使用 2 种针对 ACE 的 mAb,1G12 和 9B9)和已经接受的动力学测定法检测患者血浆中 ACE 抑制剂的敏感性,并证明基于 mAb 的测定法敏感得多。这种方法在检测已知(如胆红素和溶菌酶)和未知的 ACE 效应物/抑制剂方面也非常有效,其性质和组合在不同组织或不同患者中可能有所不同。
结论/意义:个体 ACE 的表型(以及 ACE 的构象指纹作为该方法用于 ACE 特征描述的一部分)确实变得具有信息性和临床相关性。对 ACE 构象和伴随效应物的个体间差异的认识(并依赖于)使得该方法在未来的 ACE 抑制剂个体化医学中的应用更加准确。这种(或类似的)方法可以应用于任何具有针对其不同表位的多种 mAb 的酶/蛋白。